Mobile

A Mechanism of Action study to evaluate the effects of IL-6 receptor blockade with tocilizumab (TCZ) on lipids, arterial stiffness, and markers of atherogenic risk in patients with moderate to severe ...

Mise à jour : Il y a 4 ans
Référence : EUCTR2007-001114-17

A Mechanism of Action study to evaluate the effects of IL-6 receptor blockade with tocilizumab (TCZ) on lipids, arterial stiffness, and markers of atherogenic risk in patients with moderate to severe active rheumatoid arthritis (RA)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To investigate the effect of TCZ on markers of atherogenic risk in patients with RA. Primary objectives: • To investigate the effect of 12 weeks of treatment with TCZ on small LDL-L1 particle number • To investigate the effect of 12 weeks of treatment with TCZ on arterial stiffness as assessed by pulse-wave velocity (PWV)

Critère d'inclusion

  • Rheumatoid arthritis (RA)

Liens